Rating Change
Guggenheim reiterated its Buy rating on Neurogene Inc. (NASDAQ:NGNE) on August 12, 2026.
Guggenheim reiterated its Buy rating on Neurogene Inc. (NASDAQ:NGNE) on August 12, 2026.

At publication ·
Neurogene Inc. (NASDAQ:NGNE) · reiterate
At a glance
Guggenheim reiterated its Buy rating on Neurogene Inc. (NASDAQ:NGNE) on August 12, 2026.
Neurogene Inc. operates in the Healthcare sector. The stock currently trades at $36.98 with a market capitalization of $329.3M.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurogene Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 09, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 06, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NGNE Stock Page
A rating of Buy from Guggenheim reflects the analyst's outlook on Neurogene Inc. (NASDAQ:NGNE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NGNE forecast page.
Current market data
NASDAQ · NGNE
$35.48
Down: -$0.64 · -1.77%
Live quote updated
Keep reading